San Diego, CA, USA – January 18, 2017 –HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.
Author Archive for: huyausa
This author has yet to write their bio.Meanwhile lets just say that we are proud huyausa contributed a whooping 25 entries.
Entries by huyausa
Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry
San Diego, CA, USA – March 24, 2016 –HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9th BioPharma Asia Convention 2016.
Biopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation
Shanghai, China – March 22, 2016 –HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai.
Inhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy
San Diego, CA, USA – March 15, 2016 –HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.
Eisai to commercialize HUYA’s Product in Lymphoma and Develop New Indications in Solid Tumors
San Diego, CA, USA – February 1, 2016 –HUYA Bioscience International (HUYA) President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.
Appoints Andy Claude, C.P.A., as Vice President, Finance
San Diego, CA, USA – December 23, 2015 –HUYA Bioscience International (HUYA) today announced the addition of Andy Claude, C.P.A. as Vice President, Finance. His addition to the senior management team will support the company’s international expansion.
HBI-8000 granted orphan drug designation for peripheral T-cell lymphoma in Japan
San Diego, CA, USA – December 22, 2015 –HUYA Bioscience International (HUYA), Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare (MHLW) granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).
Appoints Scott Garrett as Vice President for Commercial Planning
San Diego, CA, USA – December 15, 2015 –HUYA Bioscience International (HUYA) today announced the appointment of Scott Garrett, M.B.A. as Vice President, Commercial Planning. His addition to the senior management team will support the Company’s advancement of its lead anti-cancer drug HBI-8000 as well as the development of HUYA’s pipeline of cardiovascular products.
Appoints Dmitri Kharkevitch as Vice President for Clinical Development
San Diego, CA, USA – December 10, 2015 –HUYA Bioscience International (HUYA) today announced the appointment of Dmitri Kharkevitch, M.D., Ph.D., as Vice President, Clinical Development Oncology. This most recent addition to the senior management team supports the Company’s expansion of its clinical development programs for the lead anti-cancer drug HBI-8000.
Supports Prestigious Award Recognizing Excellence in Pharmaceutical Development
San Diego, CA, USA – December 3, 2015 –HUYA Bioscience International (HUYA) was a proud sponsor of the ‘Best New Drug’ category at the 11th Annual SCRIP Awards. Dr. Mireille Gillings was a finalist for ‘Executive of the Year’ and HUYA was a finalist for ‘Best Company in an Emerging Market’.